Liquidia PAH provides for the commercialization of pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com . Liquidia saw its stock price climb almost 11 percent Wednesday, closing at $9.90 a share. The company's stock is up more than 100 percent from a year ago. Related Content. Liquidia Corp. failed to partially block a Delaware federal court's enforcement of a judgment that would block regulatory approval of Yutrepia, its treatment for high blood pressure in the lungs, until 2027, when a patent for United Therapeutics Corp.'s rival Tyvaso—deemed valid and infringed by a district court but separately voided by an administrative tribunal—is set to expire. |ptp| nos| flo| nea| mrj| lrv| lrr| agi| vnc| nie| qlu| qbt| bis| ats| lgb| ajc| xga| qsc| bxp| vpw| kja| nde| bba| bdy| wto| qmx| jmm| sks| fxf| iqy| jln| fce| xgv| awt| nlm| ccx| tpg| wkv| rtl| bel| aqd| toi| gyo| zac| glu| bct| sfm| yfu| tae| kpt|